🔗 Visit the ClinicalTrials.gov page for NCT01553851
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | MEK and the inhibitors: from bench to bedside. | J Hematol Oncol | 2013 | 1.90 |
| 2 | ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. | Cancer Res | 2011 | 1.34 |
| 3 | The MAPK pathway across different malignancies: a new perspective. | Cancer | 2014 | 1.22 |
| 4 | A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease. | Clin Cancer Res | 2014 | 1.20 |
| 5 | BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. | Oncotarget | 2014 | 0.92 |
| 6 | Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal. | Front Oncol | 2016 | 0.80 |